CPT® Code 80368

Official Description

Sedative hypnotics (non-benzodiazepines)

Common Language Description

A laboratory test identified by CPT® Code 80368 is utilized to measure the presence of non-benzodiazepine sedative hypnotics in biological samples such as urine, serum, or plasma. Non-benzodiazepine sedative hypnotics are a class of psychoactive medications that, while providing similar therapeutic effects, side effects, and risks as traditional benzodiazepines, possess a distinct chemical structure. This class includes well-known medications such as eszopiclone (Lunesta), zaleplon (Sonata), zolpidem (Ambien), zolpidem tartrate (Intermezzo sublingual), ramelteon (Rozerem), chloral hydrate (Noctec), and dexmedetomidine hydrochloride (Precedex). The mechanism of action for most of these drugs involves binding to a specific receptor in the brain known as the omega-1 benzodiazepine receptor, which is thought to induce sleep while being less disruptive to the rapid eye movement (REM) sleep cycle compared to benzodiazepines. Notably, eszopiclone enhances gamma-aminobutyric acid (GABA) activity at receptor sites, while ramelteon functions as a melatonin receptor stimulator. These medications are primarily indicated for short-term management of insomnia, with dexmedetomidine being predominantly used in anesthesia settings. The testing process involves obtaining a blood sample through a separately reportable venipuncture or a urine sample via random void or catheterization. The analysis of these samples employs advanced techniques such as high-performance liquid chromatography-tandem mass spectrometry for eszopiclone, zolpidem, and ramelteon, while zaleplon is assessed using high-performance liquid chromatography alone. Additionally, chloral hydrate in serum and plasma is evaluated using gas chromatography, and dexmedetomidine is analyzed through gas chromatography-mass spectrometry.

1. Indications

The laboratory test associated with CPT® Code 80368 is indicated for the detection and measurement of non-benzodiazepine sedative hypnotics in patients who may be experiencing symptoms related to insomnia or other sleep disorders. This test is particularly relevant for individuals who are undergoing treatment with these medications or who may have been exposed to them. The following conditions may warrant the use of this test:

Insomnia A common sleep disorder characterized by difficulty falling asleep, staying asleep, or waking up too early, leading to daytime fatigue and impaired functioning.
Medication Monitoring Patients who are prescribed non-benzodiazepine sedative hypnotics may require monitoring to ensure therapeutic levels are maintained and to assess for potential misuse or adverse effects.
Substance Exposure Situations where there is a suspicion of non-benzodiazepine sedative hypnotic use, either for recreational purposes or in cases of accidental ingestion.

2. Procedure

The procedure for conducting the laboratory test under CPT® Code 80368 involves several key steps to ensure accurate measurement of non-benzodiazepine sedative hypnotics in the collected samples. The following procedural steps are outlined:

Sample Collection Blood samples are obtained through a venipuncture, which is a standard procedure for drawing blood from a vein. Urine samples can be collected either through random voiding or catheterization, depending on the clinical scenario and patient condition. Proper collection techniques are essential to avoid contamination and ensure the integrity of the samples.
Sample Preparation Once collected, the samples are prepared for analysis. This may involve processes such as centrifugation for blood samples to separate serum or plasma from cellular components, ensuring that only the liquid portion is tested.
Analytical Testing The prepared samples undergo specific analytical testing methods. High-performance liquid chromatography-tandem mass spectrometry is employed for the detection of eszopiclone, zolpidem, and ramelteon, providing high sensitivity and specificity. Zaleplon is analyzed using high-performance liquid chromatography alone. For chloral hydrate, gas chromatography is utilized, while dexmedetomidine is assessed using gas chromatography-mass spectrometry, which allows for precise identification and quantification of these substances.

3. Post-Procedure

After the completion of the laboratory test, the samples are analyzed, and results are generated. The expected turnaround time for results may vary based on the laboratory's processing capabilities and the specific tests performed. Clinicians will review the results to determine the presence and levels of non-benzodiazepine sedative hypnotics in the patient's system. It is important for healthcare providers to interpret these results in the context of the patient's clinical history, current medications, and any symptoms they may be experiencing. Follow-up may be necessary to discuss the findings with the patient and to make any adjustments to their treatment plan if required. Additionally, documentation of the test results and any subsequent actions taken should be maintained for compliance and continuity of care.

Short Descr	SEDATIVE HYPNOTICS
Medium Descr	DRUG SCREENING SEDATIVE HYPNOTICS
Long Descr	Sedative hypnotics (non-benzodiazepines)
Status Code	Not Valid for Medicare Purposes
Global Days	XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC)	9 - Not Applicable
Multiple Procedures (51)	9 - Concept does not apply.
Bilateral Surgery (50)	9 - Concept does not apply.
Physician Supervisions	09 - Concept does not apply.
Assistant Surgeon (80, 82)	9 - Concept does not apply.
Co-Surgeons (62)	9 - Concept does not apply.
Team Surgery (66)	9 - Concept does not apply.
Diagnostic Imaging Family	99 - Concept Does Not Apply
APC Status Indicator	Code Not Recognized by OPPS when submitted on Outpatient Hospital Part B Bill Type (12x/13x)
Type of Service (TOS)	5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS)	T2D - Other tests - other
MUE	1

90	Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number.